PVCT's 30.86% 2012 loss contributed to this index' overall loss.
Mentor Capital Cancer Immunotherapy Index Posts 11% Annual Loss in 2012 and
Adds Companies for 2013
Business Wire News Release
2013-02-19T07:55:00-05:00
SAN DIEGO--(BUSINESS WIRE)--Feb. 19, 2013-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its
proprietary Cancer Immunotherapy Index declined (-10.9%) during 2012. The equally weighted Cancer
Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ,
S&P, and NYSE Biotech Indices. For 2012 the biotech indices averaged a 32.7% gain. In comparison, during
the first six months of 2012, the Dow, S&P 500 and NASDAQ Composite indices appreciated 5.90%, 16.61%
and 15.89%, respectively.
Immunocellular Therapeutics (41%), Agenus (105%) and Celldex (158%) have led the sector with gains during
the 2012 annual period. Cancer immunotherapy pioneer, Dendreon, dominates the market capitalization of
the sector, representing 46% of the combined Cancer Immunotherapy Index total share value of $1.8 Billion.
During 2013, other newly public or now larger immunotherapy companies will be added to the proprietary
cancer index.
The Mentor Capital Cancer Immunotherapy Index companies and their reported 2012 performance follow:
Dendreon (NASDAQ:DNDN) -24.87%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +41.18%, Agenus
(NASDAQ:AGEN) +105.00%, Oncothyreon (NASDAQ:ONTY) -74.67%, Biovest International (Pink Sheets:BVTI)
-66.67%, Celldex Therapeutics (NASDAQ:CLDX) +158.08%, Northwest Biotherapeutics (NASDAQ:NWBO)
-45.90%, CEL – SCI Corp. (NYSE MKT:CVM) -6.86% , Generex Biotechnology (OTCBB:GNBT) -83.30% as a
proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc.
(Pink Sheets:PVCT) -30.86% and Advaxis, Inc. (OTCBB:ADXS) -80.93% - all for an average twelve month loss
of -10.92%.
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public
cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10,
2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer
Immunotherapy Index which can be found at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the
MNTR Company Web Site above.
Source: Mentor Capital, Inc. |
